Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1693
This examiner grants 37% of resolved cases
Samantha Lynn Schachermeyer has a portfolio of 38 resolved cases in Art Unit 1693. Her allowance rate of 36.8 percent suggests that obtaining a patent in Tech Center 1600 under her review is difficult. The 36.8 percent allowance rate highlights the importance of a well-crafted initial application to withstand a detailed review. The median days to allowance stands at 1222, reflecting a moderately paced prosecution cycle. This 1222 day timeline requires applicants to be prepared for an extended period of active engagement with the office.
The most notable data point is the interview lift of 72.6 percent. This extremely high figure indicates that interviews are nearly essential for moving an application toward allowance. Practitioners should prioritize early and frequent communication to capitalize on this high success rate for interviewed cases, which dramatically shifts the odds in the applicant's favor. Given the number of resolved cases on record, the data suggests that the path to a grant is much clearer for those who engage in direct dialogue using the 72.6 percent lift.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18761777 | BORONATED HYDROGELS AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | Boston Scientific Scimed, Inc. |
| 17995798 | METHODS OF TREATING DIABETIC KIDNEY DISEASE | Final Rejection | AbbVie Inc. |
| 18276397 | SMALL MOLECULE INHIBITORS OF CD38 AS IMMUNOSUPPRESSANTS | Final Rejection | OHIO STATE INNOVATION FOUNDATION |
| 18002301 | COMPOSITIONS COMPRISING MYO-INOSITOL AND THEIR USE IN THE PREVENTION OF POST PARTUM HAEMORRHAGE (PPH) | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 18279517 | THE USE OF EMPAGLIFLOZIN FOR THE TREATMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE | Final Rejection | The Governors of the University of Alberta |
| 17775213 | CERAMIDE ANALOG SACLAC MODULATES SPHINGOLIPID LEVELS AND MCL-1 SPLICING TO INDUCE APOPTOSIS IN ACUTE MYELOID LEUKEMIA | Final Rejection | University of Virginia Patent Foundation |
| 17923171 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | Non-Final OA | THE SCRIPPS RESEARCH INSTITUTE |
| 17782654 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND/OR TREATMENT OF DYSBIOSIS AND ANTIBACTERIAL ANTIDOTES FOR MICROBIOME-PROTECTION | Final Rejection | EUROPEAN MOLECULAR BIOLOGY LABORATORY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy